维普中文期刊产品整合服务

Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy:risk factors and survival

查看全文 作　　者：Kai-Lin [1,2,3]Chen;Jie [4]Chen;Hui-Lan [1,2,5]Rao;Ying [1,2,6]Guo;Hui-Qiang [1,2,3]Huang;Liang [7]Zhang;Jian-Yong [1,2,8]Shao;Tong-Yu [1,2,3]Lin;Wen-Qi [1,2,3]Jiang;De-Hui [9,10]Zou;Li-Yang [1,2,3]Hu;Michael Lucas [1,2,3]Wirian;Qing-Qing [1,2,3]Cai 高影响力作者 机构地区：[1]Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China;[2]Collaborative Innovation Center of Cancer Medicine;[3]Department of Medical Oncology,Sun Yat-sen University Cancer Center;[4]Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology,Radiotherapy Department Sun Yat-sen Memorial Hospital of Sun Yat-sen University;[5]Department of Pathology,Sun Yat-sen University Cancer Center;[6]Clinical Trial Center,Sun Yat-sen University Cancer Center;[7]Department of Lymphoma and Myeloma,University of Texas MD Anderson Cancer Center;[8]Department of Molecular Diagnostics,Sun Yat-sen University Cancer Center;[9]Lymphoma and Myeloma Center,Institute of Hematology and Blood Diseases Hospital;[10]State Key Lab of Experimental Method of Hematology,Chinese Academy of Medical Sciences and Peking Union of Medical College高影响力机构 出　　处：《Chinese Journal of Cancer》索引2015年第34卷第5期,共12页高影响力期刊 基　　金：supported by the National Natural Science Foundation of China (No.81372883,No.81001052);the Science and Technology Planning Project of Guangdong Province,China(No.2011B031800222);the Young Talents Project of Sun Yat-sen University Cancer Center(to QC);the Young Talents Project of Sun Yat-sen University(to QC);the Natural Science Foundation of Guangdong Province,China(No.8151008901000043);the Sister Institution Network Fund of MD Anderson Cancer Center(to HR);partly supported by the NIH through MD Anderson's Cancer Center Support Grant (No.CA016672) 摘　　要：Introduction:Hepatitis B virus(HBV) reactivation has been reported in B-cell lymphoma patients with resolved hepatitis B(hepatitis B surface antigen[HBsAg]-negative and hepatitis B core antibody[HBcAb]-positive).This study aimed to assess HBV reaaivation and hepatitis occurrence in diffuse large B-cell lymphoma(DLBCL) patients with resolved hepatitis B receiving rituximab-containing chemotherapy compared with HBsAg-negative/HBcAb-negative patients to identify risk factors for HBV reaaivation and hepatitis occurrence and to analyze whether HBV reaaivation and hepatitis affect the survival of DLBCL patients with resolved hepatitis B.Methods:We reviewed the clinical data of 278 patients with DLBCL treated with rituximab-containing therapy between January 2004 and May 2008 at Sun Yat-sen University Cancer Center,China.Prediaive faaors for HBV reaaivation,hepatitis development,and survival were examined by univariate analysis using the chi-square or Fisher's exact test and by multivariate analysis using the Cox regression model.Results:Among the 278 patients,165 were HBsAg-negative.Among these 165 patients,6(10.9%) of 55 HBcAb-positive(resolved HBV infeaion) patients experienced HBV reactivation compared with none(0%) of 110 HBcAb-negative patients(P=0.001).Patients with resolved hepatitis B had a higher hepatitis occurrence rate than HBsAg-negative/HBcAb-negative patients(21.8%vs.8.2%,P = 0.013).HBcAb positivity and elevated baseline alanine aminotransferase(ALT) levels were independent risk factors for hepatitis.Among the 55 patients with resolved hepatitis B,patients with elevated baseline serum ALT or aspartate aminotransferase(AST) levels were more likely to develop hepatitis than those with normal serum ALT or AST levels(P = 0.037,P = 0.005,respeaively).An elevated baseline AST level was an independent risk factor for hepatitis in these patients.Six patients with HBV reactivation recovered after immediate antiviral therapy,and chemotherapy was continued.HBcAb positivity,HBV reactivation,or hepatitis did not negatively affect the survival of DLBCL patients.Conclusions:DLBCL patients with resolved hepatitis B may have a higher risk of developing HBV reaaivation and hepatitis than HBsAg-negative/HBcAb-negative patients.Close monitoring and prompt antiviral therapy are required in these patients. 关 键 词：乙型肝炎病毒 B细胞淋巴瘤 危险因素 弥漫性 患者 激活 化疗 单抗
相关文献

参考文献(41)

引证文献(12)

耦合文献(25)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费